Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.120
+0.020 (1.82%)
At close: Jul 16, 2025, 4:00 PM
1.100
-0.020 (-1.79%)
After-hours: Jul 16, 2025, 5:40 PM EDT
Opus Genetics Employees
Opus Genetics had 18 employees as of December 31, 2024. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
$758,389
Profits / Employee
-$3,256,667
Market Cap
66.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 4 | 28.57% |
| Dec 31, 2023 | 14 | 5 | 55.56% |
| Dec 31, 2022 | 9 | 1 | 12.50% |
| Dec 31, 2021 | 8 | 3 | 60.00% |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IRD News
- 13 days ago - Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 23 days ago - Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewsWire
- 2 months ago - Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - GlobeNewsWire